Localized prostate cancer: what it means and what your options are

What "localized" means

It means that, on the studies performed, the tumour lies within the prostate gland: it has not gone beyond its limits, nor spread to lymph nodes or other organs. This is the situation with the widest range of treatment alternatives and the highest likelihood of long-term control.

Prostate cancer also tends to grow slowly. That is why, unlike other tumours, decisions almost never have to be made within days. That margin is a genuine advantage: it allows the workup to be completed, each option to be properly understood and — if you wish — a second opinion to be sought before committing to any treatment.

Risk drives everything: no two cases are alike

Two people with the same diagnosis may need different paths. To decide, the case is placed in a risk group by combining three elements:

• The grade of the tumour. This is what the biopsy reports through the Gleason system, now expressed as grade groups 1 to 5. It indicates how aggressive the cells look under the microscope, and it carries the most weight.
• The PSA value at the time of diagnosis.
• The clinical extent, based on examination and imaging, particularly MRI.

From that combination comes a risk group — low, intermediate or high — and from it the reasonable options follow. That is why the most useful first question in consultation is not "will you operate?" but "which risk group am I in, and why?".

In some cases additional studies are requested to rule out spread beyond the gland before deciding on treatment.

Surgery: radical prostatectomy

This means removing the whole prostate together with the seminal vesicles and, when indicated, the pelvic lymph nodes. It is one of the treatment options with curative intent in localized disease.

When performed robot-assisted, the operation is carried out through small incisions, with magnified three-dimensional vision and articulated instruments. Compared with open surgery, this translates into less bleeding, less postoperative pain and faster recovery.

When the characteristics of the tumour allow it, a nerve-sparing technique is used, aimed at protecting erectile function. It is not always possible: if the tumour lies close to those structures, cancer control takes priority, and that is discussed with you before surgery.

After the procedure a urinary catheter is needed for a few days, and examination of the surgical specimen provides definitive information about the true extent of the tumour, which sometimes differs from what was estimated beforehand.

How robotic surgery works and where it offers a real advantage →

Radiotherapy

This is the other alternative with curative intent. It can be given as external beam radiotherapy, in sessions over several weeks — now with shorter schedules than in the past — or as brachytherapy, placing the radioactive material inside the gland. In intermediate and high risk it is usually combined with hormone therapy for a defined period.

It requires neither surgery nor general anaesthesia, which makes it particularly attractive in older patients or those with coexisting conditions.

How the choice is made

This is the point that causes most confusion, so it is worth stating plainly: your treatment should be decided by a Urologic Oncologist, based on the combination of:

• The risk group and the specific characteristics of the tumour.
• Your age and life expectancy, and any conditions you already have.
• The side-effect profile of each option, which is different — not simply better or worse.
• The size of the prostate and your current urinary symptoms.
• Your personal priorities, which are a legitimate criterion and not a minor detail.

A good consultation should leave you understanding why an option is being proposed and what is given up by choosing it. If you leave unable to explain it to your family, the conversation fell short.

Continence and sexual function

This is what worries patients most and gets explained least. It deserves to be discussed openly.

After surgery it is common to leak urine at first, improving progressively over the following weeks and months; pelvic floor exercises help that recovery. Erectile function depends on whether the nerves could be spared, on your age and — decisively — on how it was before the operation. Recovery is gradual and can be supported with specific treatment.

Radiotherapy has a different profile: fewer continence problems at the start, but irritative urinary symptoms and, in some cases, rectal discomfort during treatment; erectile function tends to decline more slowly over time.

No treatment is neutral. Asking about this before deciding is not superficial: it is part of choosing well.

The hardest decision is not made in theatre

Why it matters who looks after you

In localized prostate cancer there is almost never any urgency, and that is an advantage frequently squandered. You have time to decide well, and deciding well depends on who you decide it with.

• Classifying the risk correctlyEverything else hangs on this. It requires reviewing the pathology, the MRI and, where applicable, staging studies. A misclassified case is over- or under-treated, and both carry a cost.
• Knowing when not to operateA proportion of low-risk patients need not immediate treatment but active surveillance with clear criteria. Offering it takes judgement and a willingness not to operate, which is not the same as knowing how to operate.
• Operating while preserving what can be preservedWhen surgery is the option, the difference lies in sparing the neurovascular bundles where the tumour allows it, and in not sparing them where doing so would compromise cancer control. That decision is made inside theatre and admits no middle ground.
• Managing whatever comes afterwardsIf the PSA rises again years later, its location must be found and the salvage treatment decided. Having that conversation with the person who operated on you, rather than with someone receiving an unfamiliar file, changes the response time.

Put plainly: the same tumour may end in surveillance, in surgery or in radiotherapy depending on who assesses it. Not because some operate better, but because the conversation beforehand determines the rest.

A urologic oncologist is a urologist who additionally completed a postgraduate fellowship devoted solely to urological cancer. Mine was at Centro Médico Nacional Siglo XXI, accredited by UNAM. It can be verified. What exactly changes →

What to bring to your appointment

• The full pathology report from the biopsy — not just the summary.
• The MRI and any other imaging, on disc or with digital access.
• All your PSA values with their dates.
• A list of your medications and coexisting conditions.
• Written down on paper: what your urinary and sexual function were like before the diagnosis. This is information that gets forgotten in consultation and is key to deciding.
• If you can, bring someone with you. People retain far less than they think.